| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CAY10603 | GDSC1000 | pan-cancer | AAC | 0.0024 | 0.9 |
| mRNA | narciclasine | CTRPv2 | pan-cancer | AAC | -0.0026 | 0.9 |
| mRNA | WZ4002 | CTRPv2 | pan-cancer | AAC | -0.0034 | 0.9 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | -0.0035 | 0.9 |
| mRNA | NPK76-II-72-1 | GDSC1000 | pan-cancer | AAC | -0.0021 | 0.9 |
| mRNA | LFM-A13 | GDSC1000 | pan-cancer | AAC | -0.0023 | 0.9 |
| mRNA | FTI-277 | GDSC1000 | pan-cancer | AAC | 0.0021 | 0.9 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | 0.0018 | 0.9 |
| mRNA | CUDC-101 | GDSC1000 | pan-cancer | AAC | 0.0019 | 1 |
| mRNA | OSI-930 | GDSC1000 | pan-cancer | AAC | 0.0021 | 1 |